BA
ATXS

BlackRock Advisors’s Astria Therapeutics ATXS Stock Holding History

BlackRock Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-25
Closed -$8K – 3753
2016
Q1 		$8K Buy
25
+16
+178% +$5.51K ﹤0.01% 3603
2015
Q4 		$4K Sell
9
-8
-47% -$3.84K ﹤0.01% 3738
2015
Q3 		$8K Buy
+17
New +$12.1K ﹤0.01% 3677

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BlackRock Advisors's ATXS Position: Q2 2016 in Review

BlackRock Advisors sold out of Astria Therapeutics (ATXS) in Q2 2016, closing a stake of 25 shares — an estimated $8K sold.

BlackRock Advisors first reported a position in ATXS in Q3 2015 and held it in 3 quarters. The position peaked at $8K in Q1 2016. 27 funds tracked by Wall St. Rank hold ATXS as of Q2 2016.

  • BlackRock Advisors reported no remaining Astria Therapeutics position as of Q2 2016 after selling out during the quarter.
  • BlackRock Advisors sold 25 Astria Therapeutics shares in Q2 2016, an estimated $8K.
  • BlackRock Advisors first reported a position in Astria Therapeutics in Q3 2015 and held it in 3 quarters.
  • BlackRock Advisors's Astria Therapeutics position peaked at $8K in Q1 2016.
  • 27 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2016.

Based on BlackRock Advisors's 13F filing for Q2 2016, filed 10 Aug 2016.